109047 ⎘
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor; Recombinant DNA-technology; DNA or RNA fragments; Modified forms thereof General methods applicable to biologically active non-coding nucleic acids
Methods and compositions involving miRNA and miRNA inhibitor molecules
#3002Simultaneous gene silencing and suppressing gene silencing in the same cell
#3003Method to trigger RNA interference
#3004Anti-connexin compounds targeted to connexins and methods of use thereof
#3005Methods and compositions to protect aquatic invertebrates from disease
#3006Amine cationic lipids and uses thereof
#3007RNA interference for the treatment of gain-of-function disorders
#3008Therapeutic nanoparticles and methods of use thereof
#3009Screening method
#3010Reduced size self-delivering RNAi compounds
#3011Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
#3012Method for treating fibrosis using siRNA and a retinoid-lipid drug carrier
#3013siRNA conjugate and preparation method thereof
#3014MicroRNA compounds and methods for modulating miR-122
#3015Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same
#3016Methods and compositions involving miRNA and miRNA inhibitor molecules
#3017Sugar alcohol-based compositions for delivering nucleic acid-based drugs in vivo and in vitro
#3018Peptide sequence design and use thereof for peptide-mediated siRNA delivery
#3019Extended dicer substrate agents and methods for the specific inhibition of gene expression
#3020Double-stranded nucleic acid molecule, cancer cell proliferation inhibitor and pharmaceutical agent suitable for prevention or treatment of cancer
#3021Repressor on IFN-λ promoter and siRNA against ZEB1 and BLIMP-1 to increase IFN-λ gene activity
#3022Methods and agents to increase therapeutic dystrophin expression in muscle
#3023Antisense molecules and methods for treating pathologies
#3024Feeder-free Derivation of human-induced pluripotent stem cells with synthetic messenger RNA
#3025Antisense nucleic acids
#3026Oligonucleotides for RNA interference and biological applications thereof
#3027Conjugated antisense compounds and their use
#3028Switchable aptamers
#3029Combined hairpin-antisense compositions and methods for modulating expression
#3030Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#3031Micro-RNA scaffolds and non-naturally occurring micro-RNAs
#3032Compositions and methods for modulating myeloid derived suppressor cells
#3033Single-stranded nucleic acid molecule having amino acid backbone
#3034Lipids, lipid complexes and use thereof
#3035Oligomeric compounds and compositions for use in modulation of small non-coding RNAS
#3036Exonuclease resistant polynucleotide and related duplex polynucleotides, constructs, compositions, methods and systems
#3037Induced exon inclusion in spinal muscle atrophy
#3038Means for inhibiting the expression of ANG2
#3039Lin28-mediated control of let-7 biogenesis
#3040Selective antisense compounds and uses thereof
#3041Exon skipping compositions for treating muscular dystrophy
#3042Targeting domain and related signal activated molecular delivery
#3043Methods and compositions for enhancing the efficacy and specificity of RNA silencing
#3044Modified iRNA agents
#3045Double-stranded nucleic acid molecule for gene expression control
#3046Tetrahydropyran nucleic acid analogs
#3047Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
#3048RNA interference in skin indications
#3049Methods and compositions involving miRNA and miRNA inhibitor molecules
#3050Recombinant polypeptides for membrane fusion and uses thereof
#3051Modified parvovirus useful for gene silencing
#3052Therapeutic compositions
#3053Compositions and methods for modulation of LMNA expression
#3054Gapped oligomeric compounds comprising 5′-modified deoxyribonucleosides in the gap and uses thereof
#3055Induced pluripotent stem cells with synthetic modified RNAs
#3056Targeted self-assembly of functionalized carbon nanotubes on tumors
#3057Reduction of off-target RNA interference toxicity
#3058Oligonucleotides for treating expanded repeat diseases
#3059Auto-recognizing therapeutic RNA/DNA chimeric nanoparticles (NP)
#3060Chimeric double-stranded nucleic acid
#3061Process for purifying VLPs
#3062Pharmaceutical composition for treating cancer using carbonate apatite nanoparticles
#3063Antisense design
#3064Tricyclo-phosphorothioate DNA
#3065Methods and compositions for manipulating translation of protein isoforms from alternative initiation of start sites
#3066Synthetic nanostructures including nucleic acids and/or other entities
#3067Potent LNA oligonucleotides for the inhibition of HIF-1a expression
#3068Immune tolerance inducer
#3069Method for nucleic acid delivery using hyaluronic acid
#3070Compounds and methods for modulating protein expression
#3071Dendronized polymers for nucleic acid delivery
#3072Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
#3073Slide chip for detection sensor of food-borne pathogens and preparation method thereof
#3074Synthetic lariat RNA for RNA interference
#3075Site specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
#3076Methods and compositions for the treatment of huntington's disease
#3077Modulation of pre-mRNA using splice modulating oligonucleotides as therapeutic agents in the treatment of disease
#3078Three-component biosensors for detecting macromolecules and other analytes
#3079Construction of bifunctional short hairpin RNA
#3080Clusterin antisense therapy for treatment of cancer
#3081Therapeutic nanoparticles and methods of use thereof
#3082Short interfering RNA (siRNA) analogues
#3083Method to trigger RNA interference
#3084Ribozyme for identifying modification on RNA sequence and RNA cleavage method using same
#3085Albumin production and cell proliferation
#3086Methods and compositions involving MicroRNA
#3087Cell penetrating peptides for intracellular delivery of molecules
#3088Methods for heart regeneration
#3089Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells
#3090Methods and compositions for amplification and detection of MicroRNAs
#3091Method and medicament for inhibiting the expression of a given gene
#3092Methods for fixing and detecting RNA
#3093Method and medicament for inhibiting the expression of a given gene
#3094Antibacterial antisense oligonucleotide and method
#3095Optimization of vectors for effective delivery and expression of genetic content
#3096Methods for producing interfering RNA molecules in mammalian cells and therapeutic uses for such molecules
#3097Down regulation of the gene expression by means of nucleic acid-loaded virus-like particles
#3098Compositions and methods for inhibiting expression of transthyretin
#3099Sequence-specific inhibition of small RNA function
#3100Interfering RNA delivery system and uses thereof
#3101Methods for creating and identifying functional RNA interference elements
#3102Control of gene expression
#3103TECHNIQUE FOR CLEAVING OUT PART OF POLY(A) CHAIN AND/OR 3'-TERMINAL SEQUENCE OF mRNA TO INHIBIT TRANSLATION REACTION
#3104Cochleate compositions directed against expression of proteins
#3105Phase changing formulations of nucleic acid payloads
#3106In vivo production of small interfering RNAs that mediate gene silencing
#3107pRNA multivalent junction domain for use in stable multivalent RNA nanoparticles
#3108Modified siRNA molecules and uses thereof
#3109Alternative export pathways for vector expressed RNA interference
#3110Terminator sequence-containing reverse primer for overexpression and linear DNA
#3111Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
#3112Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
#3113Uniform field magnetization and targeting of therapeutic formulations
#3114Methods and compositions for controlling efficacy of RNA silencing
#3115Amine-containing lipidoids and uses thereof
#3116Methods and compositions for screening and treating developmental disorders
#3117Micro-RNA's that regulate muscle cells
#3118Methods and compositions for selecting siRNA of improved functionality
#3119Therapeutic compounds
#3120RAAV-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
#3121Production and extraction of MicroRNA precursor as drug for cancer therapy
#3122Methods for regulating neural differentiation
#3123Individualized cancer therapy
#3124Method for evaluating redox activity of nucleic acid molecule and nucleic acid molecule having redox activity
#3125Nucleic acid/polysaccharide complex
#3126Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#3127Oligomeric compounds comprising bicyclic nucleotides and uses thereof
#3128Functional nucleic acid molecule and use thereof
#3129Compositions and methods for inhibiting expression of a target gene
#3130Methods and compositions for high efficiency transfection of siRNA
#3131SiRNA sequence-independent modification formats for reducing off-target phenotypic effects in RNAi, and stabilized forms thereof
#3132siRNA targeting TIE-2
#3133Modified siRNA molecules incorporating 5-fluoro-2′-deoxyuridine residues to enhance cytotoxicity
#3134Vector for pulmonary delivery, inducing agent, and uses
#3135Efficient protein expression in vivo using modified RNA (MOD-RNA)
#3136Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#3137Oligomeric compounds and compositions for use in modulation of small non-coding RNAS
#3138Optimized miRNA constructs
#3139Method and medicament for inhibiting the expression of a given gene
#3140Multi-conjugate of siRNA and preparing method thereof
#3141Amino acid lipids and uses thereof
#3142Small RNA-dependent translational regulatory system in cell or artificial cell model
#3143Oligonucleotide analogues targeting human LMNA
#3144Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA
#3145MicroRNAs and uses thereof
#3146Compositions and methods for treating leukemia
#3147Use of DR6 and p75 antagonists to promote survival of cells of the nervous system
#3148Chimeric oligomeric compounds for modulation of splicing
#3149Catalytic nucleic acid probes as microbial indicators
#3150Compositions and methods for characterizing and treating muscular dystrophy
#3151Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
#3152Composition and method for oligonucleotide delivery
#3153Repressor on IFN-λ promoter and siRNA against ZEB1 and BLIMP-1 to increase IFN-λ gene activity
#3154Enabling the use of long dsRNA for gene targeting in mammalian and other selected animal cells
#3155Production and utilization of a novel anti-cancer drug in therapy
#3156Promoters and terminators for use in eukaryotic cells
#3157Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy
#3158Modified iRNA agents
#3159Supercoiled minicircle DNA for gene therapy applications
#3160Lipid-polymer hybrid particles
#3161Methods and compositions for enhancing the efficacy and specificity of RNA silencing
#3162Oligonucleotide compositions with enhanced efficiency
#3163Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA
#3164Base modified oligonucleotides
#3165MicroRNA biomarkers for human breast and lung cancer
#3166Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
#3167Subunit-selective nucleic acid inhibitors of glutamate receptors
#3168Compounds and methods for modulating interaction between proteins and target nucleic acids
#3169Methods for alleviating facioscapulohumeral dystrophy (FSHD) by N siRNA molecule inhibiting the expression of DUX4-FL
#3170iRNA agents with biocleavable tethers
#3171Peptide-based in vivo siRNA delivery system
#3172Methods and kits for synthesis of siRNA expression cassettes
#3173Multiplex microfluidic device for selecting nucleic acid aptamers, and high throughput selection method for nucleic acid aptamers using same
#3174Nucleic acid molecules inducing RNA interference, and uses thereof
#3175Nucleic acids encoding FOXD3 promoter and methods to isolate FOXD3 expressing cells
#3176Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules
#3177Adeno-associated virus 2/8—micro RNA-101 therapy for liver cancer
#3178Agent for treating myelofibrosis
#3179Gene silencing by single-stranded polynucleotides
#3180Method to trigger RNA interference
#3181Modified single-stranded polynucleotides
#3182Protease degradable polypeptides and uses thereof
#3183Antagonat compositions and methods of use
#3184Compositions for targeted delivery of siRNA
#3185RNAi sequence-independent modification formats, and stabilized forms thereof
#3186Nanotopography-mediated reverse uptake platform for nucleic acid delivery and applications thereof
#3187Oligonucleotide analogues incorporating 5-aza-cytosine therein
#3188Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD)
#3189Piggy-back delivery of nucleic acids into organisms
#3190Cell permeable nanoconjugates of shell-crosslinked knedel (SCK) and peptide nucleic acids (“PNAs”) with uniquely expressed or over-expressed mRNA targeting sequences for early diagnosis and therapy of cancer
#3191Segmented micro RNA mimetics
#3192SiRNA compositions and methods for potently inhibiting viral infection
#3193DNA origami devices
#3194RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
#3195Method of deriving mature hepatocytes from human embryonic stem cells
#3196Antisense nucleic acids
#3197Modified human U1snRNA molecule, a gene encoding for the modified human U1snRNA molecule, an expression vector including the gene, and the use thereof in gene therapy
#3198Pharmaceutical composition for transcolonic absorption
#3199siRNA targeting myeloid differentiation primary response gene (88) (MYD88)
#3200Microvesicles carrying small interfering RNAs, preparation methods and uses thereof
#3201Custom designed microbubble contrast agents and techniques of ultrasound delivery optimized for gene therapy
#3202Preparation of microvesicle-siRNA complexes and use thereof in AIDS treatment
#3203Antisense oligonucleotide directed removal of proteolytic cleavage sites from proteins
#3204RNA sequence-specific mediators of RNA interference
#3205Agent for suppressing expression of dominant mutant gene
#3206Biologically active molecules for influencing virus-, bacteria-, parasite-infected cells and/or tumor cells and method for the use thereof
#3207Method of producing dicer
#3208Method of regulating gene expression
#3209Multiple exon skipping compositions for DMD
#3210Method for producing novel hiPSC by means of miRNA introduction
#3211Method for modulating double-strand break-induced homologous recombination
#3212Method to trigger RNA interference
#3213Method for producing novel hipsc by means of siRNA introduction
#3214Ligand-conjugated monomers
#3215Graft copolymer polyelectrolyte complexes for drug delivery
#3216Structurally designed shRNAs
#3217Method for controlling the amount of gene product, and agent for controlling the amount of gene product
#3218Delivery of RNA to different cell types
#3219In vivo gene silencing by chemically modified and stable siRNA
#3220Single-stranded RNAi agents containing an internal, non-nucleic acid spacer
#3221Compositions and Methods for the Delivery of Biologically Active RNAs
#3222Compounds and methods for improving cellular uptake of oligomeric compounds
#3223Method and medicament for inhibiting the expression of a given gene
#3224Single use system for sterilely producing lipid-nucleic acid particles
#3225Uniform field magnetization and targeting of therapeutic formulations
#3226Nuclease resistant double-stranded ribonucleic acid
#3227Methods and compositions for treating prostate cancer
#3228Double-stranded RNA-based nanoparticles for insect gene silencing
#3229Peptide conjugated, inosine-substituted antisense oligomer compound and method
#3230Reduced size self-delivering RNAi compounds
#3231Oligonucleotides comprising acyclic and abasic nucleosides and analogs
#3232SiRNA structure for minimizing off-target effects caused by antisense strands, and use thereof
#3233TARGETED DELIVERY TO LEUKOCYTES USING PROTEIN CARRIERS
#3234Multicomponent nucleic acid enzymes and methods for their use
#3235Methods of preparing targeted aptamer prodrugs
#3236Compositions and methods for silencing apolipoprotein B
#3237Nucleic acid functionalized nanoparticles for therapeutic applications
#3238Use of DNAzymes for analysis of an RNA sample
#3239PROMOTER, PROMOTER CONTROL ELEMENTS, AND COMBINATIONS, AND USES THEREOF
#3240Cyclic cationic lipids and methods of use
#3241Method for transfecting nucleic acid to cell and nucleic acid complex
#3242MiRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway
#3243Compositions and methods for modulation of SMN2 splicing
#3244Interfering RNA molecules
#3245RNA aptamers against BAFF-R as cell-type specific delivery agents and methods for their use
#3246General composition framework for ligand-controlled RNA regulatory systems
#3247Uniform field magnetization and targeting of therapeutic formulations
#3248Single stranded extended dicer substrate agents and methods for the specific inhibition of gene expression
#3249UNA oligomers for therapeutics
#3250Agent for suppressing expression of dominant allele
#3251Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
#3252Formulations comprising antisense nucleotides to connexins
#3253Anti-HLA-DR Antibodies Suppress Allogeneic and Xenogeneic Immune Responses to Organ Transplants
#3254Method for modulating microRNA content in living beings and the use thereof
#3255MICROBUBBLE COMPLEXES AND METHODS OF USE
#3256MODULATING PRODUCTION TRAITS IN AVIANS
#3257Nucleic acid-lipopolymer compositions
#3258Double-stranded RNA molecules with stability in mammalian body fluid, preparation and application thereof
#3259MicroRNA Signatures Predicting Responsiveness To Anti-HER2 Therapy
#3260SiRNA-mediated gene silencing
#3261COMPOSITIONS AND METHODS FOR TREATING PROSTATE CANCER
#3262Method of rapidly producing improved vaccines for animals
#3263Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts
#3264siRNA Targeting Fructose-1, 6-bisphosphatase 1 (FBP1)
#3265Human Cancer micro-RNA Expression Profiles Predictive of Chemo-Response
#3266SINGLE-WALLED CARBON NANOTUBE/BIOACTIVE SUBSTANCE COMPLEXES AND METHODS RELATED THERETO
#3267Photocleavable morpholino oligos with integral photolinkers for modulating the activity of any selected gene transcript by exposure to light
#3268In vivo gene sensors
#3269Composition For Delivery Of Genetic Material
#3270Humanized lewis-Y specific antibody-based delivery of dicer substrate siRNA (D-siRNA) against STAT3
#3271Modified U7 snRNAs for treatment of neuromuscular diseases
#3272Double-stranded oligonucleotides
#3273AGENT FOR TREATING MYELOFIBROSIS
#3274Methods and compositions to protect aquatic invertebrates from disease
#3275P53 MODULATOR AND CANCER TARGET
#3276Treatment of metastatic tumors
#32775′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
#3278Isoform of bruton's tyrosine kinase (BTK) protein
#3279ISOFORM OF BRUTON'S TYROSINE KINASE (BTK) PROTEIN
#3280NEW ISOFORM OF BRUTON'S TYROSINE KINASE (BTK) PROTEIN
#3281COMPOSITIONS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DSRNA CONTAINING MODIFIED NUCLEOTIDES
#3282COMPOSITIONS, METHODS AND USES FOR BIOSYNTHETIC PLASMID INTEGRATED CAPTURE ELEMENTS
#3283Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics
#3284METHOD OF PRODUCING TRANSCRIPTS USING CRYPTIC SPLICE SITES
#3285Compositions and methods for modulation of LMNA expression
#3286DOUBLE STRAND COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENE MODULATION
#3287KLF6 ALTERNATIVE SPLICE FORMS AND A GERMLINE KLF6 DNA POLYMORPHISM ASSOCIATED WITH INCREASED CANCER RISK
#3288MARKER FOR DETECTING MYOGENIC DISEASE AND DETECTION METHOD USING THE SAME
#3289SYNTHETIC NANOSTRUCTURES INCLUDING NUCLEIC ACIDS AND/OR OTHER ENTITIES
#3290MODULATING XRN1
#3291Nucleic Acids and Libraries
#3292Nucleic Acids and Libraries
#3293siRNA Targeting Beta Secretase (BACE)
#3294SNALP FORMULATIONS CONTAINING ANTIOXIDANTS
#3295Aptamer-mRNA conjugates for targeted protein or peptide expression and methods for their use
#3296Method and compositions involving microRNA
#3297RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#3298NUCLEIC ACID COMPOUNDS FOR INHIBITING GENE EXPRESSION AND USES THEREOF
#3299Methods for reducing protein levels in a cell
#3300MICRORNA REGULATING THE INSULIN SIGNALING PATHWAY, AND METHOD FOR SCREENING MATERIAL FOR CONTROLLING THE ACTION OF A TARGET THEREOF